Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.

Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.
复制标题

使用 miR-32-5p 通过改变 miR-32-5p/TR4/HGF/Met 信号传导抑制透明细胞肾细胞癌转移的临床前研究

DOI:
10.1002/ijc.31289
复制
发表时间:
2018-07-01
影响因子:
6.4
通讯作者:
Chang C
Chang C
中科院分区:
医学1区
文献类型:
--
作者:
Wang M;Sun Y;Xu J;Lu J;Wang K;Yang DR;Yang G;Li G;Chang C

文献摘要

参考文献

被引文献

相似文献

虽然睾丸核受体 4 (TR4) 可能促进前列腺癌 (PCa) 转移,但其在透明细胞肾细胞癌 (ccRCC) 中的作用仍不清楚。在这里,我们发现远处转移患者的 ccRCC 肿瘤中 TR4 的表达高于无转移患者,表明 TR4 可能在 ccRCC 转移中发挥积极作用。体外 ccRCC 细胞系的结果也证实了 TR4 通过改变 microRNA (miR-32-5p)/TR4/HGF/Met/MMP2-MMP9 信号传导在促进 ccRCC 细胞侵袭/迁移中发挥积极作用。机制剖析表明,miR-32-5p可以通过直接结合TR4 mRNA的3'UTR来抑制TR4蛋白表达水平,然后TR4可能通过直接结合HGF启动子上的TR4反应元件(TR4RE)来改变转录调控中的HGF/Met信号传导。然后,体外数据也证明了目前用于治疗 ccRCC 的药物舒尼替尼(Sunitinib)的疗效在针对这一新发现的 miR-32-5p/TR4/HGF/Met 信号传导后可能会增加。使用异种移植 ccRCC 细胞的体内小鼠模型进行的临床前研究证实了体外细胞系数据。总之,这些发现表明 TR4 是促进 ccRCC 转移的关键因素,用 TR4-shRNA 或 miR-32-5p 等小分子靶向 miR-32-5p/TR4/HGF/Met 信号传导可能有助于开发一种新疗法,以更好地抑制 ccRCC 转移。
While testicular nuclear receptor 4 (TR4) may promote prostate cancer (PCa) metastasis, its roles in the clear cell renal cell carcinoma (ccRCC) remains unclear. Here we found a higher expression of TR4 in ccRCC tumors from patients with distant metastases than those from metastasis-free patients, suggesting TR4 may play positive roles in the ccRCC metastasis. Results from in vitro ccRCC cell lines also confirmed TR4’s positive roles in promoting ccRCC cell invasion/migration via altering the microRNA (miR-32-5p)/TR4/HGF/Met/MMP2-MMP9 signaling. Mechanism dissection revealed that miR-32-5p could suppress TR4 protein expression levels via direct binding to the 3'UTR of TR4 mRNA, and TR4 might then alter the HGF/Met signaling at the transcriptional regulation via direct binding to the TR4-response-elements (TR4RE) on the HGF promoter. Then the in vitro data also demonstrated the efficacy of Sunitinib, a currently used drug to treat ccRCC, could be increased after targeting this newly identified miR-32-5p/TR4/HGF/Met signaling. The preclinical study using the in vivo mouse model with xenografted ccRCC cells confirmed the in vitro cell lines data. Together, these findings suggest that TR4 is a key player to promote ccRCC metastasis and targeting this miR-32-5p/TR4/HGF/Met signaling with small molecules including TR4-shRNA or miR-32-5p may help to develop a new therapy to better suppress the ccRCC metastasis.
miR-141通过控制EphA2表达是肾细胞癌增殖和转移的关键调节因子
DOI: 10.1158/1078-0432.ccr-13-3224
发表时间: 2014-05-15
影响因子: 11.5
作者:
Chen, Xuanyu;Wang, Xuegang;Zhang, Xiaoping
通讯作者: Zhang, Xiaoping
DOI: 10.1016/j.brainres.2007.06.069
发表时间: 2007-09-07
期刊: BRAIN RESEARCH
影响因子: 2.9
作者:
Chen, Yei-Tsung;Collins, Loretta L.;Chang, Chawnshang
通讯作者: Chang, Chawnshang
DOI: 10.1002/ijc.29049
发表时间: 2015-02-15
影响因子: 6.4
作者:
Ding, Xianfan;Yang, Dong-Rong;Chang, Chawnshang
通讯作者: Chang, Chawnshang
DOI: 10.1073/pnas.91.13.6040
发表时间: 1994-06-21
影响因子: 11.1
作者:
CHANG, CS;DASILVA, SL;BURBACH, JPH
通讯作者: BURBACH, JPH
DOI: 10.1073/pnas.0707594105
发表时间: 2008-02-05
影响因子: 11.1
作者:
Place, Robert F.;Li, Long-Cheng;Dahiya, Rajvir
通讯作者: Dahiya, Rajvir